JCI insight

The diabetes drug semaglutide lowers alcohol drinking and changes brain signals that calm nerve activity

Updated

Abstract

Semaglutide reduced binge-like alcohol drinking in both male and female rodents.

  • The effects of semaglutide were assessed using a drinking-in-the-dark procedure in mice and tests in rats.
  • A dose-dependent reduction in binge-like alcohol consumption was observed in mice and rats.
  • Semaglutide also decreased dependence-induced alcohol drinking in rats.
  • In alcohol-naive rats, semaglutide increased the frequency of spontaneous inhibitory signals in certain brain regions, indicating enhanced release of a calming neurotransmitter.
  • No overall change in neurotransmission was detected in alcohol-dependent rats.

Simplified

Key numbers

0.1 mg/kg
Decrease in Alcohol Intake
Semaglutide reduced self-administration of sweet alcohol in nondependent rats.
130.7%
Increase in Release
Semaglutide increased sIPSC frequency in CeA neurons from alcohol-naive rats.
0.1 mg/kg
Reduction in Noncaloric Solution Intake
Semaglutide reduced fluid intake in mice drinking saccharin-sweetened solutions.

Full Text

What this is

  • Semaglutide, a analogue, reduces alcohol consumption in rodent models.
  • The study assesses its effects on binge-like drinking and dependence-induced drinking.
  • It also examines how semaglutide modulates neurotransmission in key brain regions.

Essence

  • Semaglutide decreases binge-like and dependence-induced alcohol drinking in mice and rats, suggesting its potential as a treatment for alcohol use disorder. It modulates neurotransmission in the central amygdala and infralimbic cortex, with varying effects in alcohol-naive vs. alcohol-dependent rats.

Key takeaways

  • Semaglutide significantly reduced binge-like alcohol drinking in both male and female mice and rats, indicating its effectiveness across sexes. The reduction was dose-dependent, supporting its potential therapeutic role.
  • In alcohol-naive rats, semaglutide increased spontaneous inhibitory postsynaptic currents (sIPSCs) in the central amygdala and infralimbic cortex, suggesting enhanced release. However, in alcohol-dependent rats, the effects were mixed, indicating altered signaling.
  • Semaglutide also reduced the intake of non-alcohol caloric and noncaloric solutions, suggesting its appetite-suppressing effects extend beyond alcohol, which may be beneficial in treating alcohol use disorder.

Caveats

  • The study primarily uses rodent models, which may not fully replicate human alcohol use disorder. Further clinical trials are necessary to confirm the findings in humans.
  • The electrophysiological effects of semaglutide were inconsistent in alcohol-dependent rats, indicating that more research is needed to understand its complex interactions with signaling in the context of alcohol dependence.

Definitions

  • GABA: Gamma-aminobutyric acid, a neurotransmitter that inhibits neuronal activity and is crucial for regulating excitability in the nervous system.
  • GLP-1: Glucagon-like peptide-1, an incretin hormone involved in glucose metabolism and appetite regulation.
  • AUD: Alcohol use disorder, a chronic condition characterized by an inability to control or stop drinking despite negative consequences.

Simplified

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free